— April 1, 2026 · A Last-Resort Resistance Gene Turns Up in the U.S. Food Supply

On April 1, 2026, the U.S. Centers for Disease Control and Prevention (CDC) closed the books on a small but unusual foodborne outbreak — and in doing so recorded a first for the country. An extensively drug-resistant (XDR) strain of Salmonella, carrying a last-resort resistance gene called NDM-1, had been traced to a contaminated dietary supplement: moringa powder capsules. The outbreak was tiny, and no one died. What makes it worth your attention is not the body count. It is the gene.

Table of Contents

1. 1. What Happened
2. 2. What NDM-1 Is, and Why It Matters
3. 3. The Numbers
4. 4. What It Actually Means
5. 5. Honest Caveats
6. 6. The Takeaway
7. Sources

1. What Happened

Between late September 2025 and early January 2026, at least ten people in eight states fell ill with a strain of Salmonella Newport (a small number of related Salmonella Kentucky infections were also identified). Epidemiologic, laboratory, and traceback data pointed to a single culprit: Rosabella-brand moringa powder capsules, sold as a nutritional supplement. On February 13, 2026, Ambrosia Brands, LLC recalled the affected lots, and the FDA opened a formal outbreak investigation. By April 1, 2026, with no new cases appearing, the CDC declared the outbreak over and published clinical guidance for physicians. In that guidance the agency used a phrase that had never appeared in an American outbreak notice before: this was “the first documented outbreak of Salmonella with an NDM-1 gene in the United States.”

2. What NDM-1 Is, and Why It Matters

NDM-1 stands for New Delhi metallo-β-lactamase-1, an enzyme first characterized in 2009 in a Klebsiella sample from a patient who had been hospitalized in New Delhi. It belongs to a family called carbapenemases — enzymes that destroy carbapenems, the powerful β-lactam antibiotics (such as meropenem) that doctors hold in reserve for the most dangerous infections. When a common foodborne germ starts carrying a carbapenemase, one of medicine’s last lines of defense stops working.

The outbreak strain lived up to the “extensively drug-resistant” label. According to the CDC, it resisted amoxicillin-clavulanic acid, ampicillin, azithromycin, ceftriaxone, ciprofloxacin, meropenem, and trimethoprim-sulfamethoxazole — that is, essentially every first-line and backup antibiotic normally recommended for Salmonella. Just as concerning, NDM-1 rides on a plasmid: a small, mobile loop of DNA that bacteria routinely trade with one another. That mobility means the gene can jump from Salmonella into other species — E. coli, Klebsiella, or Acinetobacter baumannii — carrying last-resort resistance with it.

3. The Numbers

As of the April 1 close-out, the tally was small: at least 10 people infected across 8 states, 3 hospitalized, and no deaths. Illness-onset dates ran from September 26, 2025 through January 8, 2026. By the ordinary yardstick of foodborne outbreaks — where a bad year of contaminated produce or poultry can sicken hundreds — this was a minor event. That contrast is exactly why the resistance profile, not the case count, is the story.

4. What It Actually Means

It helps to separate two very different questions: what this means for a sick individual, and what it means for public health.

For the individual patient, antibiotics usually are not the point. Most healthy people who get nontyphoidal Salmonella never need antibiotics at all — they recover with fluids and rest over roughly four to seven days, and antibiotics can even prolong how long the germ is shed. Drugs are reserved for the minority with severe or invasive infection and for higher-risk groups: young infants, adults over about 50 with certain conditions, and people who are immunocompromised. For that vulnerable minority, an XDR strain is a real problem, because the familiar drugs fail. The CDC’s fallback list is short — fosfomycin may be considered for uncomplicated infections, and cefiderocol or aztreonam-avibactam for complicated ones — and the agency candidly states it does not yet have evidence-based recommendations for treating XDR Salmonella that carries a carbapenemase gene.

For public health, the location of the gene is the headline. NDM-1 has circulated for years in hospital superbugs. Finding it in a germ that arrived through a grocery-shelf supplement — on a plasmid that can spread to other bacteria — is a meaningful step in how antimicrobial resistance moves through everyday life.

5. Honest Caveats

A few things are worth stating plainly, so this is neither dismissed nor overblown:

• It was small, and it is over. Ten cases and zero deaths is a warning shot, not a catastrophe. The significance is the mechanism and the vector, not the harm this particular outbreak caused.
• Do not blame moringa the plant. Moringa oleifera is a nutritious tree used safely for centuries. The problem here was contamination of one manufacturer’s product — not the plant itself. Dietary supplements in the U.S. are not reviewed by the FDA for safety before they are sold, which is how a contaminated batch can reach shelves.
• “Untreatable by antibiotics” does not equal “untreatable.” Because most Salmonella infections are managed with supportive care and never call for antibiotics, an XDR strain changes the outcome for relatively few people. The danger is concentrated in the vulnerable minority who do need drugs.
• The lasting concern is spread, not this outbreak. The reason infectious-disease specialists took note is the risk that NDM-1 hops from this cleared outbreak strain into other, more aggressive bacteria — a slow, invisible process that no single recall ends.

6. The Takeaway

Three practical points. First, take recalls seriously and buy supplements from reputable manufacturers; a “natural” label is not a safety guarantee. Second, prevention beats treatment — ordinary food safety and hand-washing stop Salmonella far more reliably than any antibiotic cures it, and that is even more true when the usual antibiotics no longer work. Third, keep this outbreak in perspective while still learning from it: the arrival of a last-resort resistance gene in the American food supply is a genuine milestone in the story of infectious disease and antimicrobial resistance — one worth watching precisely because, this time, almost nothing went wrong.

Sources

1. Centers for Disease Control and Prevention. Clinical Overview of Extensively Drug-Resistant Salmonella Newport with an NDM-1 Gene. Published April 1, 2026. cdc.gov/salmonella/hcp/clinical-overview/xdr-salmonella-ndm1.html
2. Centers for Disease Control and Prevention (Newsroom). Extensively Drug-Resistant Salmonella Outbreak Linked to Moringa Powder Capsules. 2026. cdc.gov/media/releases/2026
3. U.S. Food and Drug Administration. Outbreak Investigation of Extensively Drug-Resistant Salmonella: Moringa Powder (February 2026). fda.gov/food/outbreaks-foodborne-illness
4. American Academy of Pediatrics, Red Book Online. Extensively Drug-Resistant Salmonella Outbreak Linked to Moringa Powder Capsules. 2026. publications.aap.org/redbook
5. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046–5054. doi:10.1128/AAC.00774-09 · PMID 19770275
6. PubMed topic search: NDM-1 Salmonella carbapenemase

Back to Table of Contents